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Introduction
Since the seventies, the incidence of neonatal group B streptococcal sepsis and meningitis has increased dramatically in all industrialized countries. 1 Today, GBS is identified as the leading cause of invasive bacterial infections in neonates. The reported attack rates for the early-onset disease (EOD) (birth to age 7 days) range from 0.5 to 4 cases per 1,000 live births. [2] [3] [4] In the late-onset form (LOD) occurring in infants aged > 1 week, the attack rate is close to 0.5 per 1,000 live births.
The early-onset form of GBS disease typically occurs in the first 24 h of life, with fulminant sepsis or pneumonia and less often with meningitis. Despite intensive supportive care, diagnostic and therapeutic progresses, these infections have remained associated to high mortality (5 -20 %) and morbidity; more than 30 % of infants recovering of meningitis develop long term neurologic sequelae. 5 In perinatal infections or EOD, GBS is transmitted vertically to the newborn from the vagina of a typically asymptomatic colonized woman during labour and delivery. In addition to colonization with GBS, other factors increase the risk for GBS EOD. These include prematurity (gestation < 37 weeks), intrapartum fever (temperature >= 38°C), duration of amniotic membrane rupture >= 18 hours, previous delivery of an infant with invasive GBS disease and GBS bacteriuria during current pregnancy. 6, 7 Because of the continuing magnitude and severity of GBS disease, several preventive strategies have been evaluated. 8, 9 The reference recommendations were published by the CDC in 1996, re-evaluated and updated 2002 and further in 2010. 10 Universal screening at 35-37 weeks' gestation for maternal GBS colonization and use of intrapartum antibioprophylaxis is currently considered to be the most effective strategy to decrease the incidence of EOD. However the cost of prenatal screening and antibiotic prophylaxis, as well as the selective pressure that antibiotics may have on the bacterial flora of mother and newborn still generate much controversy.
In Belgium, as in many European countries, national guidelines for the GBS EOD prevention are currently available since 2003. 11 Indeed, most hospitals have implemented strategies to decrease perinatal GBS infections and obstetric programs already included a GBS prevention policy but not always according to CDC guidelines. 12 As in the United States of America, despite the Belgian implemented strategy for prevention of perinatal group B streptococcal (GBS) disease, GBS remains an important cause of GBS EOD.
The majority (95%) of children with GBS EOD will become ill within the first 24 hours after birth. The management of ill neonates and/or neonates at high risk of infection is well defined, but management of healthy-appearing neonates is more problematic. An updated approach for empirical management of infants born to women, who received or should have received intrapartum antibiotic prophylaxis (IAP) to prevent GBS EOD or to treat suspected chorioamnionitis, is provided (A 1) and was adapted from international guidelines. 10, 13 Indeed, both prenatal exposure and postnatal prolonged therapy with antibiotics has been associated with the development of necrotizing enterocolitis. [14] [15] [16] [17] The main objective of developing an algorithm for management of newborns is to minimize unnecessary evaluations and antimicrobial treatment in infants whose mothers received intrapartum antimicrobial prophylaxis (IAP).
Methods
This report was developed by a national GBS working group of paediatricians of the Belgian Superior Health Council in collaboration with gynaecologists and microbiologist according to the best available evidence (A 2) and on experts' opinion when inadequate evidence was present. Management of the neonate at risk for early-onset Group B streptococcal disease (GBS EOD).
Neonates with signs of neonatal sepsis:
In any infant with clinical signs of sepsis a full diagnostic evaluation should be done and empirical antibiotic therapy (ampicillin/ amoxicillin or penicillin + aminoglycoside) should be started regardless of IAP, other obstetrical risk factors or maternal GBS status (A-II).
Because of sub-optimal sensitivity and specificity, and of poor predictive value for infection, routine use of urine antigen, cultures of mucous membranes and gastric aspirates or body surfaces are not recommended. [19] [20] [21] [22] -Clinical signs of sepsis: infant with a combination of signs as respiratory (apnea, grunting, tachypnea, cyanosis), cardiovascular (reduced capillary refill, hypotension, shock), central nervous system (lethargy, hypothermia, fever, seizures, apnoeic spells, irritability, bulging fontanel) or gastrointestinal (poor feeding, abdominal distension) disturbances.
-Full diagnostic evaluation: full blood cell count (FBC) and differential, CRP level, blood culture, lumbar puncture (LP) if feasible (CSF analysis and culture), chest X-ray, endotracheal culture (in intubated infants or if respiratory distress or lung infiltrate) to guide antibiotic treatment in blood culture negative "pneumonia" cases. 23 A lumbar puncture is indicated in all neonates with high suspicion of GBS infection especially in those with clinical signs of meningeal inflammation (seizures, apnoeic spells, irritability, bulging fontanel), in those who initially worsen with antimicrobial therapy, and all neonates with positive blood cultures. Indeed, 15% of infants with early onset GBS infection have meningitis and 20% of infants with proven GBS meningitis have a negative blood culture. 24, 25 In cases of clinical instability, antibiotic therapy should be administered and LP should be deferred and performed later until 48 hours for cell count, chemistry together with a blood glucose level for comparison and culture. An elevated CSF protein is the most sensitive parameter for GBS meningitis and a low CSF glucose is the most specific. Normal value depends on gestational age (see A 3 below). Of the infants with GBS meningitis 96% will have at least one abnormal CSF value. If meningitis is diagnosed, the dose of penicillin should be doubled and the duration of therapy extended to 2 weeks in GBS meningitis.
Aminoglycosides should be stopped as soon as blood culture confirms GBS infection.
Healthy-appearing newborn

Neonates at high risk for early onset sepsis.
Neonates born to mothers with clinical chorioamnionitis predisposes to infection with Gramnegative organisms and increases the risk of GBS infection in GBS colonized women. If a mother received intrapartum antibiotics for treatment of suspected chorioamnionitis, a limited diagnostic evaluation consisting of blood culture, FBC (including WBC differential) + CRP at 12 hours and at 36 hours should be carried out; no chest radiograph or lumbar puncture is needed. Empiric antibiotic therapy (ampicillin/amoxicillin or penicillin + aminoglycoside) should be started in these newborns regardless of clinical condition at birth or other conditions (AII). The term "chorioamnionitis" is a clinical connotation of maternal fever (> 38 °C) during labor (with or without uterine tenderness), leukocytosis, foul smelling amniotic fluid, and/or fetal tachycardia (C-III).
Neonates at low risk of early onset sepsis.
Routine use of antimicrobial prophylaxis and routine additional laboratory testing, as defined in this document is not recommended for healthy-appearing newborns whose mother received IAP. An algorithm for the management of these newborns is suggested in figure 1. In case the infant is >= 35 weeks and duration of membrane rupture was < 18 hours, then the infant should be observed for at least 48 hours, and no routine diagnostic testing needs to be 
) (B-III).
Which and when laboratory testing?
Limited evaluation: Limited evaluation includes blood culture (at birth), FBC with differential and platelets (at 6 -12 hours of life) and CRP at 12 and 36 hours.
Because of the low sensitivity and specificity at birth, results of the full blood count (FBC) can provide more information about the presence of infection if the test is not performed before 6-12 hours after delivery. 32, 33 Clinical signs are much more sensitive than any laboratory test of infection.
Therefore, treatment should rather be based on clinical signs and on maternal risk factors, (e.g. in case of inadequate IAP: gestational age and PROM). Population data reveal that late preterm infants (35-36 weeks) are at low risk for GBS disease and related mortality compared to their more premature counterparts and even term infants. 34 Therefore, in the algorithm the cut-off was set at < 35 weeks and not at 37 weeks as the definition for prematurity. Thus laboratory tests should rather be seen as a confirmation of clinical judgment (e.g. positive laboratory tests in ill infants and negative tests in healthy-appearing neonates). In order to increase the diagnostic performance, serial measurements of CRP and full blood cell count should be undertaken at least at around 12 and 36 hours of life. 35 Lower and upper limits of neutrophils count vary with postnatal age. The total and differential white blood cell count are affected by several factors besides infection, including infant age in hours (lower first hours), the method of blood sampling (lower via arterial blood sampling), the method of delivery (lower after caesarean section), maternal hypertension (lower), and infant's gender (lower in boys), infant's gestational age (lower in very low birth weight infants and premies). [36] [37] [38] The sensitivity of C-reactive protein (CRP) to predict a bacterial infection increases rapidly after birth but at least 6 to 12 hours after the onset of infection are necessary to reach abnormal level. Therefore, if blood for CRP is taken for decision making regarding initiating antimicrobial therapy, then the drawing can better be delayed for a few hours. A significant increase (CRP level above 10 mg/l) between 2 serial measurements on samples taken over the first 8-48 hours of life has a sensitivity of almost 100% for an infectious status and normal levels for the 2 samples have a negative predictive value of 90 to 100% for an infectious status. 40 The normal upper level of CRP depends on the laboratory but in general a CRP > 10 mg/L is considered a positive level. In premature infants the increase of CRP may be delayed and the level may be lower because of immaturity of the liver. 41 Sepsis should be suspected based on repeated clinical and laboratory evaluations and if sepsis is suspected, a full diagnostic evaluation should be done (see 2.1), including cultures, and empiric antibiotic therapy should be started.
Empiric antibiotic therapy
In Ill neonates are those at risk with abnormal laboratory tests should be treated with antimicrobial agents active against GBS as well as other organisms that might cause neonatal sepsis (e.g. ampicillin or penicillin + aminoglycoside). Antimicrobial switch to 3 rd generation cephalosporin (e.g. cefotaxime) is necessary in case of Gram-negative sepsis/meningitis because of increasing ampicillin resistance of E. coli. Dosage and regimen of antimicrobial agents depend of diagnosis, postnatal age and birth weight. For dosages we refer to the Sanford guide. 42 Intravenous immunoglobulins do not improve morbidity nor mortality and are not indicated. 
Future perspectives
A major change in the new guideline is that asymptomatic term neonates should not have any laboratory testing when they do not have any additional risk factors such as PROM even when GBS prophylaxis was inadequate. This will decrease unnecessary evaluations and antibiotic exposure in healthy neonates. National long-term surveillance of early onset infections in both preterm and term infants remains of high value. Not only is this important to monitor the effect of intrapartum prophylaxis on the incidence of GBS disease but also to detect emergence resistance of GBS isolates and to find emerging neonatal pathogens causing early onset sepsis. As long there is no GBS vaccine available universal screening and intrapartum antimicrobial prophylaxis is the best option for the prevention of neonatal GBS disease and mortality. Future research should focus on the value of rapid molecular testing in order to identify not only colonized mothers but also children at highest risk of invasive disease.
Signs of neonatal sepsis
Clinical maternal chorioamnionitis³ GBS prophylaxis indicated for the mother 4 Adequate GBS prophylaxis (= penicillin, ampicillin, amoxicillin or cefazolin for ≥ 4 hours before delivery) 5 • 
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